论文部分内容阅读
目的:探究诺维本联合阿霉素化疗治疗乳腺癌的临床疗效;方法:选取我院自2011年1月至2013年1月收治的88例乳腺癌患者,对所有患者采取诺维本联合阿霉素化疗治疗的方法,分析治疗后的临床效果;结果:联合治疗后完全缓解的患者有25人,部分缓解的患者28人,病情稳定的16人,恶化的19人;疾病的控制率高达78.4%,治疗后的总有效率为60.2%,患者在治疗的过程中出现的不良反应为贫血、脱发、粒细胞减少及恶心呕吐等;结论:诺维本联合阿霉素化疗治疗乳腺癌的临床效果较好,患者的依从性好,且治疗过程中的不良反应较少,值得在临床上推广应用。
OBJECTIVE: To explore the clinical efficacy of Novolin combined with doxorubicin chemotherapy in the treatment of breast cancer.Methods: Eighty-eight breast cancer patients admitted to our hospital from January 2011 to January 2013 were enrolled in this study. Results: The number of patients with complete remission after combination therapy was 25, the patients with partial remission were 28, the stable condition was 16, and the deteriorating ones were 19. The control rate of the disease was as high as 78.4%, after treatment, the total effective rate was 60.2%, patients in the course of treatment of adverse reactions such as anemia, alopecia, neutropenia and nausea and vomiting; Conclusion: Noviben combined with doxorubicin chemotherapy for breast cancer Good clinical effect, patient compliance is good, and the adverse reactions in the course of treatment less, it is worth to promote the clinical application.